151 related articles for article (PubMed ID: 31339076)
1. Investigation of Binding Characteristics of Phosphoinositide-dependent Kinase-1 (PDK1) Co-crystallized Ligands Through Virtual Pharmacophore Modeling Leading to Novel Anti-PDK1 Hits.
Mansi IA; Al-Sha'er MA; Mhaidat NM; Taha MO; Shahin R
Med Chem; 2020; 16(7):860-880. PubMed ID: 31339076
[TBL] [Abstract][Full Text] [Related]
2. Structure based drug design of Pim-1 kinase followed by pharmacophore guided synthesis of quinolone-based inhibitors.
Swellmeen L; Shahin R; Al-Hiari Y; Alamiri A; Hasan A; Shaheen O
Bioorg Med Chem; 2017 Sep; 25(17):4855-4875. PubMed ID: 28760531
[TBL] [Abstract][Full Text] [Related]
3. Ligand Based Pharmacophore Modeling Followed by Biological Screening Lead to Discovery of Novel PDK1 Inhibitors as Anticancer Agents.
Mansi I; Al-Sha'er MA; Mhaidat N; Taha M
Anticancer Agents Med Chem; 2020; 20(4):476-485. PubMed ID: 31889497
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets.
Shahin R; Swellmeen L; Shaheen O; Aboalhaija N; Habash M
J Comput Aided Mol Des; 2016 Jan; 30(1):39-68. PubMed ID: 26685860
[TBL] [Abstract][Full Text] [Related]
5. Discovery of new heat shock protein 90 inhibitors using virtual co-crystallized pharmacophore generation.
Al-Sha'er MA; Mansi I; Khanfar M; Abudayyh A
J Enzyme Inhib Med Chem; 2016; 31(sup4):64-77. PubMed ID: 27569779
[TBL] [Abstract][Full Text] [Related]
6. Discovery of new JNK3 inhibitory chemotypes via QSAR-Guided selection of docking-based pharmacophores and comparison with other structure-based pharmacophore modeling methods.
Tuffaha GO; Hatmal MM; Taha MO
J Mol Graph Model; 2019 Sep; 91():30-51. PubMed ID: 31158642
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of novel Akt1 inhibitors as anticancer agents using virtual co-crystallized pharmacophore generation.
Al-Sha'er MA; Mansi I; Almazari I; Hakooz N
J Mol Graph Model; 2015 Nov; 62():213-225. PubMed ID: 26485540
[TBL] [Abstract][Full Text] [Related]
8. Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Taha MO; Al-Sha'er MA; Khanfar MA; Al-Nadaf AH
Eur J Med Chem; 2014 Sep; 84():454-65. PubMed ID: 25050878
[TBL] [Abstract][Full Text] [Related]
9. Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile.
Sestito S; Bacci A; Chiarugi S; Runfola M; Gado F; Margheritis E; Gul S; Riveiro ME; Vazquez R; Huguet S; Manera C; Rezai K; Garau G; Rapposelli S
Eur J Med Chem; 2021 Dec; 226():113895. PubMed ID: 34624821
[TBL] [Abstract][Full Text] [Related]
10. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
Zhang X; Zhong S
Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
[TBL] [Abstract][Full Text] [Related]
11. Discovery of New Phosphoinositide 3-kinase Delta (PI3Kδ) Inhibitors via Virtual Screening using Crystallography-derived Pharmacophore Modelling and QSAR Analysis.
Al-Sha'er MA; Al-Aqtash RA; Taha MO
Med Chem; 2019; 15(6):588-601. PubMed ID: 30799792
[TBL] [Abstract][Full Text] [Related]
12. Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening.
Bobkova EV; Weber MJ; Xu Z; Zhang YL; Jung J; Blume-Jensen P; Northrup A; Kunapuli P; Andersen JN; Kariv I
J Biol Chem; 2010 Jun; 285(24):18838-46. PubMed ID: 20385558
[TBL] [Abstract][Full Text] [Related]
13. Fragment-based lead discovery to identify novel inhibitors that target the ATP binding site of pyruvate dehydrogenase kinases.
Akaki T; Bessho Y; Ito T; Fujioka S; Ubukata M; Mori G; Yamanaka K; Orita T; Doi S; Iwanaga T; Ikegashira K; Hantani Y; Nakanishi I; Adachi T
Bioorg Med Chem; 2021 Aug; 44():116283. PubMed ID: 34274549
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new PKN2 inhibitory chemotypes via QSAR-guided selection of docking-based pharmacophores.
Al-Sha'er MA; Basheer HA; Taha MO
Mol Divers; 2023 Feb; 27(1):443-462. PubMed ID: 35507210
[TBL] [Abstract][Full Text] [Related]
15. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.
Shahin R; Taha MO
Bioorg Med Chem; 2012 Jan; 20(1):377-400. PubMed ID: 22112539
[TBL] [Abstract][Full Text] [Related]
16. Ligand-based computer aided drug design reveals new tropomycin receptor kinase a (TrkA) inhibitors.
Shahin R; Mansi I; Swellmeen L; Alwidyan T; Al-Hashimi N; Al-Qarar'h Y; Shaheen O
J Mol Graph Model; 2018 Mar; 80():327-352. PubMed ID: 29454290
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a Potent Allosteric Kinase Modulator by Combining Computational and Synthetic Methods.
Kroon E; Schulze JO; Süß E; Camacho CJ; Biondi RM; Dömling A
Angew Chem Int Ed Engl; 2015 Nov; 54(47):13933-6. PubMed ID: 26385475
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
Vyas VK; Ghate M; Goel A
J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
[TBL] [Abstract][Full Text] [Related]
19. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods.
Abutayeh RF; Taha MO
J Mol Graph Model; 2019 May; 88():128-151. PubMed ID: 30703688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
